SCHEDULE: Vanguard Group Divests Amgen Stake Amid Internal Realignment

The Vanguard Group reported a 0% beneficial ownership in Amgen Inc. common stock following an internal realignment that disaggregated reporting.

Summary

• The Vanguard Group filed an Amendment No. 11 to Schedule 13G for Amgen Inc.
• The filing indicates that The Vanguard Group now beneficially owns 0% of Amgen Inc.'s Common Stock.
• This change is a result of an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions of The Vanguard Group, Inc. will report beneficial ownership separately, in accordance with SEC Release No. 34-39538.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these disaggregated subsidiaries and/or business divisions.
• The aggregate amount beneficially owned by The Vanguard Group is 0 shares, representing 0% of the class.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. It primarily reflects an administrative change in The Vanguard Group's reporting structure rather than a direct positive or negative assessment of Amgen Inc. or a significant shift in investment strategy.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding Amgen Inc.'s future performance or The Vanguard Group's investment strategy beyond the reporting realignment.

Industry Context

StockSavvy.ai notes that internal realignments leading to disaggregated reporting are common among large asset managers like The Vanguard Group. This particular filing reflects a procedural change in how Vanguard's various entities report their holdings, rather than a strategic divestment decision related to Amgen's performance. It aligns with regulatory guidance for complex organizational structures.

Stakeholder Impact

• Shareholders of Amgen Inc. should be aware that The Vanguard Group, as a single reporting entity, no longer holds a significant beneficial ownership stake, though its underlying funds and subsidiaries may still hold shares and will report separately.
• Investment professionals should understand that this is a reporting change, not necessarily a full divestment by all Vanguard-managed funds.

Key Dates

Recommendation

This filing is purely administrative, reflecting a change in how The Vanguard Group reports its beneficial ownership due to an internal realignment. It does not provide any new information regarding Amgen Inc.'s financial performance, strategic outlook, or operational health. Therefore, a seasoned investor would likely maintain their current position on Amgen based solely on this filing, awaiting more substantive news.

Keywords

Amgen Inc, Vanguard Group, Schedule 13G, Beneficial Ownership, SEC Filing, Institutional Ownership, Common Stock, Investment Management, Realignment